Tuberculosis vaccine in late-stage trial as COVID-19 protection


Texas A&M College of Medicine is leading a consortium of research hospitals and medical schools in a Phase 4 trial to determine if the century-old tuberculosis vaccine can help blunt the damage from COVID-19, at least until a vaccine for the new coronavirus has been proven safe and effective.
"Scientists have known for decades that the tuberculosis vaccine, called bacille Calmette-Guerin, or BCG, improves immunity against some viruses," The Texas Tribune reported back in May, when the trial was just getting started. Jeffrey Cirillo, the Texas A&M microbial pathogenesis and immunology professor who is leading the trial, told Politico on Thursday that about 100 people have already been vaccinated, 200-300 more will get their shots over the next two weeks, and the goal is 1,800 subjects in the "randomized, blinded, placebo-controlled trial."
The TB vaccine has been used more than a billion times around the world, but it's not commonly used in the U.S., except to fight bladder cancer. The researchers at Texas A&M, Baylor College of Medicine, Harvard's School of Public Health, Cedars Sinai Medical Center, and the University of Texas MD Anderson Cancer Center are hoping the vaccine ramps up the immune system to fight off the disease, as it does the cancer cells. A similar trial is being conducted in the Netherlands.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The U.S. researchers will monitor the volunteers for six months, looking for statistically significant differences between those who get the BCG vaccine and the group that gets a placebo shot. "We're also doing a cognitive study in parallel to evaluate the cognitive effects of COVID-19," Cirillo told Politico's Myah Ward, using before-and-after MRIs and cognitive assessments to see if the vaccine reduces COVID-19's mental impairments. The vaccine is most effective in the first two to three years, he added, and if it is found to be effective, it could be used either as a stop-gap measure until a coronavirus vaccine arrives or in tandem with that vaccine to make it more effective.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Hostile architecture is 'hostile — to everybody'
Instant Opinion Opinion, comment and editorials of the day
-
Why are federal judges criticizing SCOTUS?
Today's Big Question Supreme Court issues Trump case rulings 'with little explanation'
-
September 8 editorial cartoons
Cartoons Monday’s political cartoons include Donald Trump booed at the U.S. Open, a hidden message in the Epstein Files and a new bird in Florida
-
New York court tosses Trump's $500M fraud fine
Speed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year